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Investigations on Cancer Cell
Biological Effects of CDK8 Inhibitor Q-12

Abstract

by Zhixin Lu
University of the Pacific
2018

Over the past two decades, protein kinases have been intensively investigated as
targets to treat neoplastic diseases. Many protein kinase inhibitors not only have
therapeutic potential but are becoming invaluable reagents for the study of cell signaling.
We aspired to use our Cyclin-Dependent Kinase 8 inhibitor, Q-12, as a probe for
biomarker discovery for CDK8 inhibitor sensitive tumor types. Q-12 shows potent
inhibition of cell viability and induction of apoptosis process in some triple-negative
breast cancer and colorectal cancer cell lines in vitro. Western blot results indicate that
the reduction of STAT1 phosphorylation could be a robust indicator of CDK8 target
engagement in all three cancer cell lines used upon Q-12 treatment. Q-12 treatment of
triple-negative breast cancer cell line (MDA-MB-468) decreases STAT1 phosphorylation
but increases STAT3 phosphorylation. Q-12 activity in MDA-MB-468 cell is dependent
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on the activation of STAT3 phosphorylation. All results suggest that there may be a
critical STAT1 to STAT3 ratio that may serve as a biomarker for CDK8 inhibitor
sensitivity. In this precision medicine era, the discovery of biomarker is urgently needed
to minimize the risks of severe side-effects by traditional chemotherapy and improve
diagnosis and monitor therapy response across a wide spectrum of disease, especially
heterogenous type of disease, like cancer.
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Background
Cyclin Dependent Kinase
Cyclin-dependent kinases (CDKs) are a protein kinases family whose activity
depends on a regulatory subunit – a cyclin. CDKs are present in a variety of key
regulatory pathways in all known eukaryotic cells and phosphorylate their substrates on
serines and threonines (1). CDKs play important roles in the control of cell division and
modulate transcription in response to several extra- and intracellular cues (2). Over the
course of evolution, both CDK and cyclin gene families have independently undergone a
significant number of functional specializations (3).
Many of the interactions between specific mammalian CDKs and cyclins have
been reported in vitro. CDKs are considered a potential target for anti-cancer treatment.
At present, some CDK inhibitors such as seliciclib, which is undergoing clinical trials,
have been found to produce apoptosis in treated cancerous cells of non-small cell lung
cancer (NSCLC) and other cancers (4). Palbociclib and ribociclib are both orally active,
highly selective reversible inhibitors of CDK4 and CDK6 that are approved by the U.S.
Food and Drug Administration (FDA) for hormone receptor-positive metastatic breast
cancer in combination with specific endocrine therapies (5).
In an evolutionary analysis of CDK and cyclin proteins in metazoans and their
unicellular relatives, Cao., el (3) found that the CDK family could be divided into eight
subfamilies. Seven subfamilies (CDK1/2/3, CDK5, CDK7, CDK 20, CDK8/19, CDK9
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and CDK10/11) are conserved in metazoans and fungi, with CDK4/6 subfamily found
only in eumetazoans.
It is very likely that new targets within the CDK family will be explored in the
near future for therapy of cancer or other diseases.
As for main function of cyclin-dependent kinase 8 in cancer, it responds to several
intracellular signaling pathways, and it has been linked to many different processes,
including cellular growth, proliferation and differentiation (7).
One of the most important activities of CDK8 is associating kinase complexes
such as P-TEFb or TFIIH to phosphorylate important regulatory sites within the STAT
transcription factor family. STAT transcription factors play an important role in immune
response and cancer development (4). CDK8 was found to phosphorylate STAT1 at the
S727 site and was identified as a key regulator of STAT1 (6).
CDK8 has multiple targets and phosphorylates several transcription factors,
affecting their stability and activity. The role of CDK8 in colorectal cancer is
documented by far the best in regulation of β-catenin-dependent gene expression.
Evidence suggests that CDK8 functions as a potent oncogene in colon cancer through
WNT/β-catenin signaling pathway coactivating within the p53 transcriptional program
(8,9).
An interesting study (10) by the Dyson lab emphasized the importance of CDK8
for β-catenin activity in a process involving the transcriptional regulator E2F1. In human
cells, E2F1 strongly repressed β-catenin-dependent transcription and induced degradation
of β-catenin. CDK8 was found to bind and phosphorylate E2F1 in vitro, suggesting that
CDK8 inhibits the repressive activity of E2F1 towards β-catenin. It appears that CDK8
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acts directly and indirectly to both enhance β-catenin transcriptional activity and to
release it from the inhibitory effect of E2F1. Active E2F1 was found to repress the
activity of β-catenin transcription and promote cell apoptosis and this activity was found
to be antagonized by a direct CDK8 phosphorylation at Ser375 (11).
There is a CDK8 study (12) that found transfection of MicroRNA-26b (miR-26b)
mimics into breast cancer cell lines (MDA-MB-231 and MCF-7 cells) significantly
suppressed cellular proliferation by directly interacting with the CDK8 3’UTR and
downregulated CDK8 mRNA and protein levels in breast cancer cells.
The aforementioned studies suggest that CDK8 is a promising novel target in
oncology and presents a potentially attractive target for small molecule intervention to
precisely act on context-related gene expression (13). In 2013 to 2014, many CDK8specific inhibitors are found in patent applications. With a deeper understanding of very
specific CDK8 activity in cancer, we are hoping to reach a robust responder hypothesis
and personalized clinical approach (13,14).
Previous work done by Dr. Russu et al (15) has identified a novel kinase
inhibitor known as Q-12, a novel compound that contains the direct attachment of the
quinazoline fragment to the piperazinylpyrimideine scaffold (Figure 1), which has shown
moderate selectivity toward CDK8 and c-KIT, another protein kinase involved in cellular
signal transduction pathways.

N
N

N
N

N
N

Figure 1. Chemical structure of Q-12
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To test the potential of Q-12 to bind with the human kinome that was designed to
target, a kinase binding assay was used to exam the ability of 10 µM of Q-12 to interfere
with the binding of a given kinase with an immobilized, ATP directed agent. A single
dose of 10 µM was chosen to allow for the detection of the kinases able to bind Q-12,
followed by dose-response binding experiments. The competition with ATP for the
binding and inhibition of CDK8 kinase and KIT kinases, is displayed as the dissociation
binding constant (Kd) in Table 1.

Table 1. Kinase binding and inhibition data for Q-12.
Kinase

Kd (µM)

CDK8

0.46

KIT

2.5

KIT(D816H) mutant

1.3

KIT(D816V) mutant

0.11

Q-12 exhibited obvious tendency to bind strongly in the ATP binding site of wildtype and/or mutant members of the CDK8 and KIT subfamilies, which indicated that Q12 is an ATP competitive inhibitor of cyclin dependent kinase 8 (CDK 8). Of the wild
type kinases, Q-12 had the highest affinity for CDK8.
An anti-proliferative activity test was performed through screening Q-12 (Figure
1) against the NCI-60 tumor cell line panel, which revealed that Q-12 was effective at
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inhibiting select cell lines (Table 2). Cell lines that contained APC mutations showed
apparent resistance to Q-12.

Table 2. GI50 (µM) values for Q-12 against selected cell line with corresponding AKT
pathway activation and PTEN/APC mutation status.
Cell Line
MDA-MB-468
RPMI-8226
NCI-H23
SF-295
HCT-116
BT-549
K-562
NCI/ADR-Res
T-47D
KM12
SW-620
HCC-2998
HT29
COLO-205
OVCAR-3
HCT-15
SK-OV-3

Q-12 GI50
0.05
0.31
0.44
0.31
0.27
1.3
0.47
0.63
0.71
12.6
12.8
15.9
15.5
30.4
11.2
19.4
25.5

APC Mutant
No
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Among all cell lines in NCI-60 cell panel, triple-negative breast cancer cell line,
MDA-MB-468 shows the most sensitivity to Q-12 (GI50=0.06 µM). The colon cancer
cell line, HCT-116, the only colon cancer cell line without APC mutation shows high
sensitive to Q-12 (GI50= 0.27 µM) as well.
Table 3 indicates that the activity of Q-12 is likely due to CDK8 inhibition,
instead of KIT inhibition. As shown Imatinib significantly inhibits the tyrosine kinase
activity of KIT, compare to Q-12. Imatinib did not have potent GI50 value profile in
HCT-116 cell line and other cell lines in NCI-60 cell panel, while Q-12 did.
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Table 3. Kinase binding ability and GI50 (µM) values of c-KIT inhibitors (Q-12 and
Imatinib) against HCT-116 cell line.

Breast Cancer
An estimated 1.67 million new breast cancer cases were diagnosed in 2012 (25%
of all cancers). Breast cancer is the second most common cancer in the world and ranks
as the fifth cause of death from cancer overall. It is the most frequent cancer in women
both in more and less developed regions with slightly more cases in less developed
regions (16).
Breast cancer is highly heterogenous and can be histologically differentiated into
21 subtypes on the basis of cell morphology and growth. Based on different gene
expression profiling, breast cancer can be molecularly categorized in at least four
subgroups with different prognosis and sensitivity to treatment (17).
The main molecular classification of breast cancer has been distinguished by gene
expression profiling into intrinsic subtypes by Peru et at (18). In clinical practice,
routinely used subtypes of breast cancer are categorized based on the profiles of three
markers, including hormonal receptors: estrogen, progesterone receptors and growth
factor receptor: human epidermal growth factor receptor 2 (HER2). Based on receptor
levels, breast cancer can be divided into luminal A, luminal B, HER2 enriched and triple
negative (19). Luminal A type of breast cancers express estrogen receptor (ER) and/or
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progesterone receptor (PR) but lack HER2 amplification. They are relatively less
aggressive and slow growing. Compare to luminal A type, luminal B type is more
aggressive (20) and also overexpress HER2. As the name indicates, HER2 enriched
subtype of breast cancers have amplified HER2 expression but lack the expression of
both hormonal receptors and they have poor prognosis compare to luminal subtypes (21).
Triple negative breast cancers (TNBC) are the most aggressive and recurring type
of breast cancers with the poorest prognosis of all subtypes. The 5-year survival rate of
TNBC patients is 77%, which is significantly lower compared to 93% in non-TNBC
patients (22). Besides lacking estrogen receptor (ER), progesterone receptor (PR) and
HER2 amplification, TNBC also often overexpress the EGFR (23). Besides
overexpression of EGFR, lack of the identification of common oncogenic driver makes
TNBC highly challenging for targeted therapy.
Based on TNBC molecular profiles, many studies have worked to classify TNBC
into different subtypes. Lehmann et al. classified TNBC into six subgroups based on
unique gene expression profiling and ontologies, including two basal-like (BL1 and
BL2), a mesenchymal (M), a mesenchymal stem-like (MSL), an immunomodulatory
(IM) subtype, and a luminal androgen receptor (LAR) subtype (24).
Although extensive TNBC molecular profiling has been established, there is no
targeted therapy for TNBC so far, which limit the treatment options to traditional
chemotherapy, radiation and surgery. Because of the different genetic and epigenetic
makeups and molecular characteristics of TNBC, there is a need for establishing targeted
therapy directed towards specific tumor pathology or signaling pathways to minimize
severe side-effects of unnecessary and ineffective treatments. Drug sensitivity based
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phenotypic profiling of TNBC and biomarker-based patient stratification in clinical trials
will also play an important role in the field of modern precision medicine.
Colorectal Cancer
Cancer is a disease characterized by the unchecked division and survival of
abnormal cells. When this type of abnormal growth occurs in the colon or rectum, it is
called colorectal cancer (CRC) (25). In 2017, there were estimated 95,520 new cases of
colon cancer and 39,910 cases of rectal cancer diagnosed in the US. Approximately
4.6% of men (1 in 22) and 4.2% of women (1 in 24) will be diagnosed with CRC in their
lifetime (26).
Adenomatous polyposis coli (APC) and its regulation of β-catenin plays a key
role in colon cancer initiation and development. APC is a protein that in humans is
encoded by the APC gene, which is classified as a tumor suppressor gene. Mutation of
APC has been found in more than 80% of all colorectal carcinomas and adenomas plays
an important role in the progression and early development of colorectal cancer (27,28).
In the absence of functional APC, Wnt/β-catenin signaling pathway is constitutively
activated. Consequently, β-catenin is deregulated and promotes aberrant transcription of
its target genes (29). Besides the ability of regulating the total cellular level of β-catenin,
APC is also involved in protein transport and cell adhesion by modulating E-cadherin
localization (30). To better understand the molecular mechanisms of APC function in βcatenin degradation, a study (31) has been done to examine the effects of APC mutations
on β-catenin phosphorylation, ubiquitination and degradation in different colon cancer
cell lines. Results suggested that APC regulates β-catenin phosphorylation and
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ubiquitination by distinct domains under different and complicated molecular
mechanisms.
Following study (32) on the post-transcriptional modifiers of β-catenin that
participate in colon cancer, CDK8 was found amplified in most types of colon cancers.
All observations indicated that CDK8 with a strong suppressor of E2F1 can regulate βcatenin activity, which brought up a potential treatment trend for colon cancer. Targeting
the CDK8 kinase activity appears to have clinical value and benefit in not only colorectal
cancer, but also other β-catenin-driven malignancies (33).
The treatment of colorectal cancer in clinic has advanced rapidly over the past
several decades, including improvements in surgical techniques and chemotherapy.
However, it has also become increasingly clear that treatment outcomes vary widely
based on tumor-specific molecular features (34). At the same time, there are many
temporary and long-term side-effects coming along during traditional cancer treatment.
Targeted therapy is a new area of colorectal cancer drug development resulting
from increased understanding of the molecular changes involved in cancer occurrence.
These drugs target specific molecules involved in tumor growth and progression and have
different, often less severe side effects than conventional chemotherapy drugs (25,34).
Altogether, targeting the CDK8 kinase activity appears to have clinical value and benefit
in not only colorectal cancer, but also other β-catenin-driven malignancies (33).
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Aim of study
The main aim of the study is to understand cancer cell biological effects of CDK8
inhibitor Q-12 and the mechanisms of anti-proliferative effect of Q-12 in order to further
identify potential biomarkers for human cancer sensitivity to CDK8 inhibitors.
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Materials and methods
Cell lines, chemicals and antibodies: MDA-MB-468 human breast cells, COLO205 human colon cells and HCT-116 human colon cells were obtained from ATCC,
USA. MDA-MB-468 and COLO-205 were grown in Gibco® RPMI-1640 medium
(Thermo Fisher Science, San Jose, CA, USA), HCT-116 was grown in McCoy’s 5a
medium (Hyclone, Logan, Utah). All media were supplemented with 10% FBS (Gemini
Biological Products, Calabasas, CA), 1% Antibiotic-Antimycotic mixture of Penicillin-G,
Streptomycin sulfate and Amphotericin B (Thermo Fisher Science, San Jose, CA, USA).
The cells were maintained in a humidified incubator at 37 °C with 5% CO2. Q-12 stock
solution: 3.3 mg Q-12 into 1 mL DMSO to make 10 mM Q-12 stock solution. Antibodies
to STAT1, p-STAT1 (Ser727), p-STAT3 (Tyr705), β-catenin, IAP family (Livin,
Survivin, XIAP, C-IAP1, C-IAP2), Bcl-2 family (Bcl-xL, Bcl-2, p-Bcl-2 (Ser70), p-Bcl-2
(Thr56), Mcl-1) and GAPDH were obtained from Cell Signaling Technology Inc
(Beverly, MA, USA).
Measurement of cellular viability: Cells were grown in T25 flask format at a
density of 1×106 cells/ flask. After 24 h of culture, cells were treated with DMSO
(vehicle) or 10 µM Q-12 for the indicated time period. Cell lines were sub cultured by
enzymatic digestion with 0.25% trypsin/EDTA solution when they reached
approximately 70-80 % confluency. Floating cells and adherent cells were collected after
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the various treatments. Cells were washed twice with 1× PBS and re-suspended in fresh
media for cell viability assay. Cell viability was measured with the Muse Cell Analyzer
(Millipore, Hayward, CA, USA) using the Muse Count and Viability Kit (Millipore,
Hayward, CA, USA) which differentially stains viable and dead cells based on their
permeability to two DNA binding dyes. Data were presented as proportional viability
(%).
Quantification of apoptosis by Annexin V labeling: For apoptosis profiling assay,
cells were treated with DMSO (vehicle) or 10 µM Q-12 for 24 h. Detached and adherent
cells were collected and incubated with Annexin V and 7-AAD, a dead cell marker, for
20 min at room temperature in dark. The events for live, dead early and late apoptotic
cells were counted with the Muse Cell Analyzer (Millipore, Hayward, CA, USA).
Western blotting analysis: After treatment of MDA-MB-468, COLO-205 and
HCT 116 cells with 10 µM Q-12 for 24 h, cells were collected and washed twice with
ice-cold 1×HBSS, then lysed in Cell Lysis Buffer (Cell Signaling Technology Inc,
Beverly, MA, USA), supplement with protease inhibitor (Sigma, USA) on ice for 10 min
before scrapping. Cell lysates were then centrifuged for 10 min at 13,000 rpm at 4 °C.
Protein concentration of lysates was determined by BCA protein assay kit (Thermo
Scientific, San Jose, CA, USA) and the lysates were adjusted with lysis buffer. Proteins
were separated using SDS-PAGE and subsequently transferred to nitrocellulose
membranes (Thermo Scientific, San Jose, CA, USA). The blots were blocked with 5 %
BSA (20 mM Tris HCL, pH 7.5, 137 mM NaCl and 0.05 % Tween-20) at room
temperature for 1 h. Incubation with specific primary antibodies was performed in
blocking buffer overnight at 4°C. After washing with TBST, the blots were incubated
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with secondary antibody (IRDye 800 CW Donkey anti-rabbit 926-32213) for 1 h. To
ensure equal protein loading, GAPDH was used as an internal control. The protein bands
were detected and quantified with the Odyssey infrared imaging system (LI-COR
biosciences, Lincoln, NE, USA).
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Results

Chapter 1. CDK8 inhibitor Q-12 effects on cancer cell line viabilities and apoptosis
induction
1.1 Q-12 effects on cancer cell line viabilities
From GI50 value for Q-12 against selected cancer cell lines (Table 2), Q-12 shows
anti-proliferative function. To examine the anticancer activity of Q-12 on breast cancer
and colorectal cancer cells in vitro, we first examined the effect of Q-12 on cell
proliferation of MDA-MB-468, COLO-205 and HCT-116 cells.

Figure 2. Cell viability of Q-12 treated cell lines vs control. Data represent the mean
±SD of at least three independent experiments. Student's t test was performed to
determine the significance (p=<0.001).
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Exponentially growing MDA-MB-468, COLO-205 and HCT-116 were treated
with vehicle (DMSO) and 10 µM Q-12 for 72 h. Our results show that the exposure of
the MDA-MB-468, COLO-205 and HCT-116 cells to Q-12 decreased cellular viability.
Cells were assayed with the Muse Cell Analyzer as described by the manufacturer.
1.2 Q-12 effects on cancer cell line apoptosis induction
Next, we investigated whether the observed growth inhibition upon Q-12
treatment was associated with induction of apoptosis. Annexin V binding was carried out
using Annexin V & Dead Cell kit (Millipore). Cells were treated with DMSO or 10 µM
Q-12 for 24 h. Detached and adherent cells were collected and stained with Annexin V
and 7-AAD. Then the events for early and late apoptotic cells were counted with the
Muse Cell Analyzer as described in Materials and Methods.

Figure 3. Q-12 induced apoptosis in cancer cell lines, control vs treated. Data represent
the mean ±SD of at least three independent experiments. Student's t test was performed
to determine the significance (p=<0.001).
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Following 24 hours of treatment, Annexin V staining was detected in cells treated
with 10 µM of Q-12 (Figure 2), indicating that MDA-MB-468 and COLO-205 cells were
undergoing apoptosis upon Q-12 treatment.
1.3 Inhibitor of apoptosis and pro-survival Bcl-2 family protein expression in
cancer cell lines
To further understand the role of Q-12 in apoptosis in MDA-MB-468 and COLO205 cell lines, we used Western blotting to detect inhibitors of apoptosis proteins (IAP)
family and pro-survival Bcl-2 family in non-treated cancer cells (Figure 4).

Figure 4. Western blotting analysis of IAP family (c-IAP1, c-IAP2, Survivin, XIAP,
Livin) and Bcl-2 Family (p-Bcl-2(Ser70), p-Bcl-2(Thr56), Bcl-2, Bcl-xL, Mcl-1) in
MDA-MB-468 and COLO-205 cell lines. Blots in figure are represented of three
independent experiments performed in triplicate.
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The expression of Survivin, XIAP, Bcl-2 and Mcl-1 are relatively high in MDAMB-468 cell line and the expression of XIAP, Bcl-2, Mcl-1 and Livin are relatively high
in COLO-205 cell line (Figure 6,7). These are the proteins we chose to investigate
further with Q-12 treatment.
1.4 Q-12 effects on cancer cell line inhibitor of apoptosis and pro-survival
Bcl-2 protein expression
We focused on Survivin, XIAP, Bcl-2 and Mcl-1 in MDA-MB-468 cell line and
XIAP, Bcl-2, Mcl-1 and Livin in COLO-205 cell line upon 10 µM Q-12 treatment to see
how Q-12 affected those protein expressions.

Figure 5. A. Bcl-xL, Mcl-1, Survivin and XIAP expression in MDA-MB-468 cell line
upon 24 h 10 µM Q-12 treatment. B. Bcl-xL, Mcl-1, Livin and XIAP expression in
COLO-205 cell line upon 24 h 10 µM Q-12 treatment. Blots in figure are represented of
three independent experiments performed in triplicate.
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Among all those high expressed IAP and pro-survival Bcl-2 family members, we
found out that the expression of Mcl-1 was downregulated upon Q-12 treatment in both
MDA-MB-468 (30% decrease) and COLO-205 (70% decrease) cell lines, which
indicates Q-12 can modulate the expression Mcl-1 in those cell lines.
1.5 Q12 effects on cancer cell line pro-apoptosis Bcl-2 protein expression
We further studied the expression of common pro-apoptosis Bcl-2 proteins (BAD,
BOK, BIM, BIK, NOXA, BID, PUMA, BAX and BAK) upon 10 µM Q-12 treatment.

Figure 6. Pro-apoptosis Bcl-2 Family expression (BAD, BOK, BIM, BIK, NOXA, BID,
PUMA, BAX and BAK) in MDA-MB-468 cell line upon 24 h 10 µM Q-12 treatment.
Blots in figure are represented of three independent experiments performed in triplicate.

Among all pro-apoptosis Bcl-2 family, PUMA and BAK expression were upregulated upon 24 h 10 µM Q-12 treatment. There are three-fold differences between
PUMA expression between control and Q-12 treated group and 1.75-fold differences
between BAK expression between control and Q-12 treated group.
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1.6 Discussion
Programmed cell death (PCD) plays an important role in determining cancer cell
fate. Apoptosis, autophagy and programmed necrosis are the three main forms of PCD,
which could be distinguished by their morphological differences (35).
Apoptosis was first described by Kerr et al. (36) with characteristics of cell
shrinkage, nuclear condensation and fragmentation, membrane blebbing or loss of
adhesion. Studies indicated that autophagic cells may commit suicide by undergoing cell
death to cope with excessive stress (37). The third type of PCD is necrosis. In this type
of programmed cell death, the cell could be found swelling, organelle dysfunction and
lysis. The cross-talk among apoptosis, autophagy and programmed necrosis was found
under certain circumstances in cancer cells. Among those three types, apoptosis has now
been widely accepted as a dominant tumor-suppression mechanism.
Bcl-2 family of proteins can program cancer cells commit to apoptosis by
interaction between its three subfamilies: anti-apoptosis Bcl-2 family, pro-apoptosis Bcl2 family and Bcl-2 homology regions 3 (BH3) (38). The initial cell death signal is
guided by BH3 - only protein group, including BAD, BID, BIM, PUMA and NOXA,
which have in common only at BH3 interaction domain. When BH3-only proteins are
induced or activated, they interact and pair with core Bcl-2 family proteins, such as Mcl1, BAX, BAK, to promote apoptosis. BH3-only proteins can be activated posttranslationally and their expression can also be induced by transcription factors (39).
According to the result of apoptosis protein expression of MDA-MB-468 cell line
upon Q-12 treatment, expression of pro-apoptosis proteins, PUMA and BAK were upregulated. Mcl-1, one of pro-survival Bcl-2 protein members, was down-regulated. At
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the same time, PUMA and BAK, as BH3 domain only protein, can be recognized and
paired with Mcl-1, which will shift the equilibrium to apoptosis more dramatically (40).
That may explain the apoptosis process happened in MDA-MB-468 cell line upon Q-12
treatment. Since Q-12 is affecting gene transcription of apoptosis proteins, we further
investigated the transcription factors that may involve in Q-12 modulation.
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Chapter 2. CDK8 inhibitor Q-12 effects on transcription factor proteins

2.1 Q-12 effects on transcription factor proteins: β-catenin and STAT1
In the cell nucleus, β-catenin interacts with the TCF/LEF transcription factors to
drive the transcription of WNT target genes, which is essential for β-catenin oncogenic
activity (41). CDK8, as a colon cancer oncogene, has been found amplified in certain
subset of colon cancers and playing an important role in the regulation of nucleus βcatenin transcription activity. STAT1, is a direct substrate of CDK8. The
phosphorylation of STAT1 at Ser 727 site has been demonstrated as a pharmacodynamic
biomarker of CDK8 activity (42). Based on that, we turned to investigate the expression
of both β-catenin and p-STAT1 (Ser 727) upon CDK8 inhibitor Q-12 treatment.

Figure 7. β-catenin and p-STAT1 Expression in MDA-MB-468 and colon cancer lines:
COLO-205 and HCT-116 upon 24 h10 µM Q-12 treatment. Blots in figure are
represented of three independent experiments performed in triplicate.
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In both colorectal cancer cell lines, COLO-205 and HCT-116, there is an obvious
decrease of β-catenin content. If β-catenin is important for the survival of colon cancer
cell lines like the other study reported (41), it makes sense that the decrease of colon
cancer cell viability is related to the decrease of β-catenin expression. While, in triplenegative breast cancer cell line, MDA-MB-468, there isn’t much change of β-catenin
upon Q-12 treatment. As for STAT1 expression, all three cancer cell lines have a
decrease of STAT1 phosphorylation at Ser 727 site, which is assumably going to affect
gene expression.
Here we have both β-catenin and p-STAT1 expression being modulated by Q-12
in colon cancer cell lines, HCT-116 and COLO-205, but only p-STAT1 was modulated in
the breast cancer cell line.
One study (43) defined STAT1 as a novel transcription target of the nucleus
EGFR-STAT3 transcription complex in breast cancer cell lines. They characterized
STAT3 can enhance STAT1 gene expression and STAT transcription factors are key
regulators of cell proliferation, apoptosis and tumor progression. They also considered
the compensatory mechanism between STAT transcription factors, especially STAT1 and
STAT3. Besides the crosstalk between STAT1 and STAT3, CDK8 was found to have
the role of phosphorylating the transactivation domain (TAD) of STAT1, STAT3, and
STAT5, which regulates the transcriptional activity of the STATs (44). The central role
of CDK8 in STAT-dependent cytokine responses make it a promising therapeutic target
within the STAT pathway. This evidence leads us to further study STAT3 expression in
those cancer cell lines upon Q-12 treatment.
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2.2 Q-12 effects on transcription factor protein: STAT3
Signal transducer and activator of transcription (STAT) family proteins are key
regulators of cell proliferation, apoptosis and tumor progression. Among them, STAT3
plays a dual role in tumor inflammation and immunity by promoting pro-oncogenic
inflammatory pathways, such as interleukin-6 (IL-6) pathway, and by involving in
STAT-1 anti-tumor immune responses (45). STAT3 can also exert either oncogenic or
anti-cancer effects through transcriptional regulation of target genes in cancer cells
directly or being modulating tumor angiogenesis and anti-tumor immune response
indirectly (46). The alternations of the balanced expression and/ or activation of STAT1
and STAT3 appears important for further developing promising compound that could
regulate the STAT1:STAT3 equilibrium in the design of cancer therapeutic interventions,
which lead us further studied the STAT3 expression upon Q-12 treatment in COLO-205
and MDA-MB-468 cell lines.

Figure 8. STAT3 and p-STAT3 (Tyr705) expression in MDA-MB-468 and COLO-205
cell lines upon 24 h 10 µM Q-12 treatment. Blots in figure are represented of three
independent experiments performed in triplicate.
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From the observation of western blotting result, there is no change as for total
STAT3 expression upon Q-12 treatment in both COLO-205 and MDA-MB-468 cell
lines. For p-STAT3 (Tyr 705), the expression is low and there wasn’t change between
the control and treatment groups in COLO-205; but, there is a definitely up-regulation in
MDA-MB-468 upon Q-12 treatment.
A study (47) specifically focused on cell lines with EGFR overexpression,
including MDA-MB-468 cell line, has showed that activation of STAT3 phosphorylation
can reduce MDA-MB-468 cell viability and induce apoptosis through either EGF
(through EGFR) or OSM (IL6 family member). They also show that siRNA of STAT3
can slightly protect the cells. Their findings indicate that STAT3 serves as a positive
mediator of EGF-induced apoptosis in MDA-MB-468 cells. Another study (48) from the
Lo group reported for the first time that STAT1 gene expression could be enhanced by
STAT3 in the presence of ErbB family of receptor tyrosine kinases, including EGFR,
EGFRvⅢ and HER2. The positive association between expression levels of STAT1 and
STAT3, involving transcriptional activation of the STAT1 gene by STAT3. In summary,
based on literature and our results, it is likely that the STAT1:STAT3 balance is closely
controlled by the inflammatory signals and growth factors. The balance will further
determine the cell fate.
Since we’ve observed apoptosis effect in MDA-MB-468 cells, we want to
investigate whether STAT3 activation was important for the previous apoptosis effect.
Our hypothesis is by inhibiting phosphorylated STAT3 activity in MDA-MB-468 cells,
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the cell viability decrease caused by Q-12 will be attenuated, which was confirmed by
following experiment.
2.3 STAT3 inhibitor experiment - Cell Viability
Cryptotanshinone (CPT) is a selective STAT3 inhibitor with IC50 of 4.6 µM in a
cell-free assay, strongly inhibits phosphorylation of STAT3 Tyr705, with a small effect
on STAT3 Ser727, but none against STAT1 nor STAT5. We examined the cell viability
of MDA-MB-468 cells upon 72 h three different treatment conditions.

Figure 9. Effect of STAT3 inhibitor on Q-12 treated and untreated MDA-MB-468 cells.
Data represent the mean ±SD of three independent experiments.

Compared to control, MDA-MB-468 cell viability with 10 µM CPT alone had an
nonsignificant decrease much, which indicating the CPT isn’t toxic to MDA-MB-468 cell
line. The second group with co-treatment of 10 µM CPT and 10 µM Q-12 had more cell
death than CPT alone group, which indicates that Q-12 can still induce the cell death
process in the presence of CPT, but not as much as the third group, which was Q-12
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alone. These results show that CPT can rescue MDA-MB-468 cells from treatment with
Q-12, suggesting that STAT3 phosphorylation plays an important part in the Q-12mediated killing the MDA-MB-468 cells. In all, Q-12 activity in MDA-MB-468 cell line
is dependent on the activation of STAT3 phosphorylation.
To further understanding the role of STAT3 in apoptosis induction upon Q-12
treatment in MDA-MB-468 cell, we further studied the expression of Bcl-2 family
member: PUMA, BAK and Mcl-1, which have been previously shown their involvement
in Q-12 treatment.
2.4 PUMA, BAK, Mcl-1 expression upon co-treatment with Q-12 and STAT3
inhibitor
For the experiment, we used control groups, Q-12 treatment groups and Q-12 and
CPT co-treatment groups.

Figure 10. Effect of co-treatment with Q-12 and STAT3 inhibitor on expression of Mcl-1,
BAK, PUMA in MDA-MB-468 cells. Blots in figure are represented of three independent
experiments performed in triplicate.
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Compare to control group, the expression of p-STAT3 (Ser727) had 2-fold
increase upon Q-12 treatment. The expression of p-STAT3 (Ser727) in CPT and Q-12
co-treatment group decreased 2-fold compared to Q-12 treatment group, which indicated
the CPT was able to inhibit p-STAT3 activation at Ser727 site, which was caused by Q12 in MDA-MB-468 cells. Mcl-1 expression was decreased due to Q-12 treatment, but
co-treatment with CPT and Q-12 restored normal expression level of Mcl-1. The proapoptosis protein, PUMA, was upregulated by Q-12, while its expression was attenuated
by CPT and Q-12 co-treatment, which similarly to Mcl-1 links its expression to STAT3
phosphorylation. Another pro-apoptosis protein BAK, was not modulated by CPT cotreatment. STAT3 inhibitor, CPT, regulated apoptosis proteins: Mcl-1 and PUMA,
which were modulated by Q-12. These results suggest that Q-12 activity in MDA-MB468 cell line is dependent on the activation of STAT3 phosphorylation.
2.5 Discussion
From the above results of the expression of Mcl-1, BAK and PUMA in MDAMB-468 cells upon co-treatment with Q-12 and STAT3 inhibitor, we concluded that Mcl1 and PUMA were modulated by Q-12 and p-STAT3 was synergistically involved in
apoptosis process, which was induced by Q-12 in MDA-MB-468 cells. BAK was not
involved in STAT3 phosphorylation upon CPT treatment. The decrease of BAK
expression may be due to the indirect reaction of the cells upon Q-12 treatment, not
linking to STAT3 signaling.
STAT3 activation can also occur through interleuin-6 (IL-6), epidermal growth
factor, vascular endothelial growth factor, etc. (43) IL-6 was shown to serve as an
activator of STAT3 in breast cancer. A positive correlation between IL-6 and p-STAT3
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expression levels was found in primary breast cancers and IL-6 family of cytokines (49).
In 2016, a study (50) confirmed the existence of a feedback loop: ILK-Akt-NF-kB-IL-6.
This signal loop was shown to activate E2F1 expression through STAT3/cyclin
D1/CDK2 signaling. Since E2F1 is a well-known cell cycle regulator and CDK8 is one of
the important kinases which negatively regulates E2F1. It also has been shown (51) that
there is a direct link between E2F1 and apoptotic machinery, especially the expression
level of the pro-apoptotic BH3-only proteins PUMA, NOXA, BIM and Hrk/DP5.
The above experimental evidence and literature presented suggest that Q-12
inhibits STAT1 phosphorylation and promotes STAT3 phosphorylation, which results in
modulating the expression of key anti- and pro-apoptotic proteins Mcl-1 and PUMA.
The change in balance between Mcl-1 and PUMA likely results in the promotion of
apoptosis in MDA-MB-468 cells. The specific mechanism is likely due to CDK8
inhibition, which is known to phosphorylate STAT1, and may additionally involve E2F1.
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Conclusions
In MDA-MB-468 and COLO-205 cell lines, Q-12 modulated transcriptional
factor p-STAT1 reduction. In colorectal cancer cell line, COLO-205, Q-12 induced βcatenin reduction, but not in triple negative breast cancer cell line, the MDA-MB-468.
The expression of p-STAT3 (Ser727) was modulated by Q-12 in MDA-MB-468 cell line
only. Further, inhibiting p-STAT3 increase due to Q-12 treatment by CPT was shown to
rescue the MDA-MB-468 cell viability. CPT inhibited the modulation of apoptosis
proteins, Mcl-1 and PUMA, due to Q-12 treatment. Q-12 activity in MDA-MB-468 cell
line is dependent on the activation of STAT3 phosphorylation.
Studies (33) have shown that CDK8 is an important modulator of both β-catenin
and E2F1, whereas CDK8 enhances the activity of β-catenin, it represses the activity of
E2F1 in colorectal cancers. Consequently, the amplification of CDK8 may act as a
switch, allowing increased β-catenin-dependent transcription that is also resistant to E2F1
inhibition. So, the inhibition of CDK8 combined with the activation of E2F1, may be
useful as a two-pronged strategy to target cancer cells that are driven by deregulated βcatenin activity (10).
Our results indicated that STAT3 activation and apoptotic proteins: PUMA and
Mcl-1 play an important role in Q-12 regulation in MDA-MB-468 cell line. Whether
E2F1 is the key regulator in the apoptosis process induced by Q-12 and how Q-12
modulates E2F1 expression still needs to be further investigated. One way to probe E2F1
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engagement upon Q-12 treatment in MDA-MB-468 cell line is to use small interfering
RNA to prevent the re-activation of E2F1. SiRNA of E2F1 will interfere with the
expression of E2F1 genes with complementary nucleotide sequences by degrading its
mRNA after transcription. If knocking down E2F1 protects the cell from Q-12, which
will suggest that E2F1 activation would be critical for the apoptosis process in the MDAMB-468 cells upon Q-12 treatment and confirm p-STAT3 involvement through the IL-6
feedback loop (50).
To study the mechanisms of anti-proliferative effect of Q-12 is an important and
necessary step to further identify potential biomarkers for human cancer sensitivity to
CDK8 inhibitors. Biomarkers could help predict a priori whether an individual patient
will respond to the treatment of choice as well as provide an early distinction of
responders and non- responders during therapy. In the future, clinical predictions based
on molecular biomarkers will greatly improve clinical care and patient outcomes.
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